Unlocking Nucleic Acid Sensing Pathway Drug Targets
Kelly Pike, PhD, Head of Translational Sciences and Scientific Affairs, Ventus Therapeutics and Thomas Tuschl, PhD, Professor of RNA Molecular Biology, The Rockefeller University
Innate Immunity and Elusive Targets
Marcelo Bigal, MD, PhD, President and CEO of Ventus Therapeutics and Judith Lieberman, MD, PhD, Professor of Pediatrics, Harvard Medical School
Prime Time for the Inflammasome
Richard A. Flavell, PhD, D.Sc, FRS, HHMI Investigator, Sterling Professor of Immunobiology, Yale School of Medicine and Michael Crackower, PhD, Chief Scientific Officer, Ventus Therapeutics
Tackling Neuroinflammation to Treat Major Brain Diseases
Anick Auger, MSc, Head of Pharmacology, Ventus Therapeutics and Marcelo Bigal, MD, PhD, President and CEO, Ventus Therapeutics
Small Molecules Are About to Be Big Again
Jason Burch, PhD, Head of Platform Technologies, Ventus Therapeutics
Water Dynamics and a New Era for Computational Chemistry
Thomas Kurtzman, PhD, Professor, Department of Chemistry, Lehman College, City University of New York and Dan McKay, BSc, MSc, Head of Computational Chemistry, Ventus Therapeutics
